Literature DB >> 31597757

In Vivo Validation of the Viral Barcoding of Simian Immunodeficiency Virus SIVmac239 and the Development of New Barcoded SIV and Subtype B and C Simian-Human Immunodeficiency Viruses.

Sirish Khanal1, Christine M Fennessey1, Sean P O'Brien1, Abigail Thorpe1, Carolyn Reid1, Taina T Immonen1, Rodman Smith1, Julian W Bess1, Adrienne E Swanstrom1, Gregory Q Del Prete1, Miles P Davenport2, Afam A Okoye3,4, Louis J Picker3,4, Jeffrey D Lifson1, Brandon F Keele5.   

Abstract

Genetically barcoded viral populations are powerful tools for evaluating the overall viral population structure as well as assessing the dynamics and evolution of individual lineages in vivo over time. Barcoded viruses are generated by inserting a small, genetically unique tag into the viral genome, which is retained in progeny virus. We recently reported barcoding the well-characterized molecular clone simian immunodeficiency virus (SIV) SIVmac239, resulting in a synthetic swarm (SIVmac239M) containing approximately 10,000 distinct viral clonotypes for which all genetic differences were within a 34-base barcode that could be tracked using next-generation deep sequencing. Here, we assessed the population size, distribution, and authenticity of individual viral clonotypes within this synthetic swarm using samples from 120 rhesus macaques infected intravenously. The number of replicating barcodes in plasma correlated with the infectious inoculum dose, and the primary viral growth rate was similar in all infected animals regardless of the inoculum size. Overall, 97% of detectable clonotypes in the viral stock were identified in the plasma of at least one infected animal. Additionally, we prepared a second-generation barcoded SIVmac239 stock (SIVmac239M2) with over 16 times the number of barcoded variants of the original stock and an additional barcoded stock with suboptimal nucleotides corrected (SIVmac239Opt5M). We also generated four barcoded stocks from subtype B and C simian-human immunodeficiency virus (SHIV) clones. These new SHIV clones may be particularly valuable models to evaluate Env-targeting approaches to study viral transmission or viral reservoir clearance. Overall, this work further establishes the reliability of the barcoded virus approach and highlights the feasibility of adapting this technique to other viral clones.IMPORTANCE We recently developed and published a description of a barcoded simian immunodeficiency virus that has a short random sequence inserted directly into the viral genome. This allows for the tracking of individual viral lineages with high fidelity and ultradeep sensitivity. This virus was used to infect 120 rhesus macaques, and we report here the analysis of the barcodes of these animals during primary infection. We found that the vast majority of barcodes were functional in vivo We then expanded the barcoding approach in a second-generation SIVmac239 stock (SIVmac239M2) with over 16 times the number of barcoded variants of the original stock and a barcoded stock of SIVmac239Opt5M whose sequence had 5 changes from the wild-type SIVmac239 sequence. We also generated 4 barcoded stocks from subtype B and C SHIV clones each containing a human immunodeficiency virus (HIV) type 1 envelope. These virus models are functional and can be useful for studying viral transmission and HIV cure/reservoir research.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  barcoded virus; nonhuman primates; simian immunodeficiency virus; viral models

Mesh:

Substances:

Year:  2019        PMID: 31597757      PMCID: PMC6912102          DOI: 10.1128/JVI.01420-19

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  Most rhesus macaques infected with the CCR5-tropic SHIV(AD8) generate cross-reactive antibodies that neutralize multiple HIV-1 strains.

Authors:  Masashi Shingai; Olivia K Donau; Stephen D Schmidt; Rajeev Gautam; Ronald J Plishka; Alicia Buckler-White; Reza Sadjadpour; Wendy R Lee; Celia C LaBranche; David C Montefiori; John R Mascola; Yoshiaki Nishimura; Malcolm A Martin
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-05       Impact factor: 11.205

2.  Nonhuman Primate Models and Understanding the Pathogenesis of HIV Infection and AIDS.

Authors:  Ronald S Veazey; Andrew A Lackner
Journal:  ILAR J       Date:  2017-12-01

3.  Early replication block of human immunodeficiency virus type 1 in monkey cells.

Authors:  R Shibata; H Sakai; M Kawamura; K Tokunaga; A Adachi
Journal:  J Gen Virol       Date:  1995-11       Impact factor: 3.891

4.  Cross-neutralization of human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus isolates.

Authors:  M Robert-Guroff; K Aldrich; R Muldoon; T L Stern; G P Bansal; T J Matthews; P D Markham; R C Gallo; G Franchini
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

5.  Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus.

Authors:  Jinyan Liu; Khader Ghneim; Devin Sok; William J Bosche; Yuan Li; Elizabeth Chipriano; Brian Berkemeier; Kelli Oswald; Erica Borducchi; Crystal Cabral; Lauren Peter; Amanda Brinkman; Mayuri Shetty; Jessica Jimenez; Jade Mondesir; Benjamin Lee; Patricia Giglio; Abishek Chandrashekar; Peter Abbink; Arnaud Colantonio; Courtney Gittens; Chantelle Baker; Wendeline Wagner; Mark G Lewis; Wenjun Li; Rafick-Pierre Sekaly; Jeffrey D Lifson; Dennis R Burton; Dan H Barouch
Journal:  Science       Date:  2016-08-18       Impact factor: 47.728

Review 6.  Using nonhuman primates to model HIV transmission.

Authors:  Christine M Fennessey; Brandon F Keele
Journal:  Curr Opin HIV AIDS       Date:  2013-07       Impact factor: 4.283

7.  Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge.

Authors:  Boris Julg; Lawrence J Tartaglia; Brandon F Keele; Kshitij Wagh; Amarendra Pegu; Devin Sok; Peter Abbink; Stephen D Schmidt; Keyun Wang; Xuejun Chen; M G Joyce; Ivelin S Georgiev; Misook Choe; Peter D Kwong; Nicole A Doria-Rose; Khoa Le; Mark K Louder; Robert T Bailer; Penny L Moore; Bette Korber; Michael S Seaman; Salim S Abdool Karim; Lynn Morris; Richard A Koup; John R Mascola; Dennis R Burton; Dan H Barouch
Journal:  Sci Transl Med       Date:  2017-09-06       Impact factor: 19.319

8.  Genetically-barcoded SIV facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy.

Authors:  Christine M Fennessey; Mykola Pinkevych; Taina T Immonen; Arnold Reynaldi; Vanessa Venturi; Priyanka Nadella; Carolyn Reid; Laura Newman; Leslie Lipkey; Kelli Oswald; William J Bosche; Matthew T Trivett; Claes Ohlen; David E Ott; Jacob D Estes; Gregory Q Del Prete; Jeffrey D Lifson; Miles P Davenport; Brandon F Keele
Journal:  PLoS Pathog       Date:  2017-05-04       Impact factor: 6.823

9.  A single gp120 residue can affect HIV-1 tropism in macaques.

Authors:  Gregory Q Del Prete; Brandon F Keele; Jeannine Fode; Keyur Thummar; Adrienne E Swanstrom; Anthony Rodriguez; Alice Raymond; Jacob D Estes; Celia C LaBranche; David C Montefiori; Vineet N KewalRamani; Jeffrey D Lifson; Paul D Bieniasz; Theodora Hatziioannou
Journal:  PLoS Pathog       Date:  2017-09-25       Impact factor: 6.823

10.  Defining early SIV replication and dissemination dynamics following vaginal transmission.

Authors:  Claire Deleage; Taina T Immonen; Christine M Fennessey; Arnold Reynaldi; Carolyn Reid; Laura Newman; Leslie Lipkey; Timothy E Schlub; Celine Camus; Sean O'Brien; Jeremy Smedley; Jessica M Conway; Gregory Q Del Prete; Miles P Davenport; Jeffrey D Lifson; Jacob D Estes; Brandon F Keele
Journal:  Sci Adv       Date:  2019-05-29       Impact factor: 14.136

View more
  10 in total

1.  CD8+ T cells fail to limit SIV reactivation following ART withdrawal until after viral amplification.

Authors:  Afam A Okoye; Derick D Duell; Yoshinori Fukazawa; Benjamin Varco-Merth; Alejandra Marenco; Hannah Behrens; Morgan Chaunzwa; Andrea N Selseth; Roxanne M Gilbride; Jason Shao; Paul T Edlefsen; Romas Geleziunas; Mykola Pinkevych; Miles P Davenport; Kathleen Busman-Sahay; Michael Nekorchuk; Haesun Park; Jeremy Smedley; Michael K Axthelm; Jacob D Estes; Scott G Hansen; Brandon F Keele; Jeffery D Lifson; Louis J Picker
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 14.808

2.  Antibody-mediated depletion of viral reservoirs is limited in SIV-infected macaques treated early with antiretroviral therapy.

Authors:  Adrienne E Swanstrom; Taina T Immonen; Kelli Oswald; Cathi Pyle; James A Thomas; William J Bosche; Lorna Silipino; Michael Hull; Laura Newman; Vicky Coalter; Adam Wiles; Rodney Wiles; Jacob Kiser; David R Morcock; Rebecca Shoemaker; Randy Fast; Matthew W Breed; Joshua Kramer; Duncan Donohue; Tyler Malys; Christine M Fennessey; Charles M Trubey; Claire Deleage; Jacob D Estes; Jeffrey D Lifson; Brandon F Keele; Gregory Q Del Prete
Journal:  J Clin Invest       Date:  2021-03-15       Impact factor: 14.808

3.  The gift of a lifetime: analysis of HIV at autopsy.

Authors:  Frank Maldarelli
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

Review 4.  So Pathogenic or So What?-A Brief Overview of SIV Pathogenesis with an Emphasis on Cure Research.

Authors:  Adam J Kleinman; Ivona Pandrea; Cristian Apetrei
Journal:  Viruses       Date:  2022-01-12       Impact factor: 5.048

5.  Highlights of the 9th edition of the Conference on HIV Persistence During Therapy, 10-13 December 2019, Miami, USA.

Authors:  Christina K Psomas; Karl Salzwedel; Mario Stevenson; Guido Poli; Jean-Pierre Routy; David Margolis; Nicolas Chomont; Alain Lafeuillade
Journal:  J Virus Erad       Date:  2020-04-30

Review 6.  Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models.

Authors:  David S Khoury; Adam K Wheatley; Mitchell D Ramuta; Arnold Reynaldi; Deborah Cromer; Kanta Subbarao; David H O'Connor; Stephen J Kent; Miles P Davenport
Journal:  Nat Rev Immunol       Date:  2020-11-02       Impact factor: 53.106

Review 7.  New Latency Reversing Agents for HIV-1 Cure: Insights from Nonhuman Primate Models.

Authors:  Katherine M Bricker; Ann Chahroudi; Maud Mavigner
Journal:  Viruses       Date:  2021-08-06       Impact factor: 5.048

8.  The mucosal barrier and anti-viral immune responses can eliminate portions of the viral population during transmission and early viral growth.

Authors:  Ryan V Moriarty; Athena E Golfinos; Dane D Gellerup; Hannah Schweigert; Jaffna Mathiaparanam; Alexis J Balgeman; Andrea M Weiler; Thomas C Friedrich; Brandon F Keele; Miles P Davenport; Vanessa Venturi; Shelby L O'Connor
Journal:  PLoS One       Date:  2021-12-02       Impact factor: 3.752

9.  Longitudinal deep sequencing informs vector selection and future deployment strategies for transmissible vaccines.

Authors:  Megan E Griffiths; Alice Broos; Laura M Bergner; Diana K Meza; Nicolas M Suarez; Ana da Silva Filipe; Carlos Tello; Daniel J Becker; Daniel G Streicker
Journal:  PLoS Biol       Date:  2022-04-19       Impact factor: 9.593

10.  Transient viral replication during analytical treatment interruptions in SIV infected macaques can alter the rebound-competent viral reservoir.

Authors:  Taina T Immonen; Christine M Fennessey; Leslie Lipkey; Abigail Thorpe; Gregory Q Del Prete; Jeffrey D Lifson; Miles P Davenport; Brandon F Keele
Journal:  PLoS Pathog       Date:  2021-06-18       Impact factor: 6.823

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.